Ethiopian Food and Drug Authority Advisory Board Holds Inaugural Meeting Under Council of Ministers Regulation

• The Ethiopian Food and Drug Authority's Advisory Board held its first meeting on August 15, 2025.
• Council of Ministers Regulation No. 531/2023 governs the advisory board's organization, powers, and responsibilities.
• Pharmaceutical companies operating in Ethiopia should be aware of potential updates to EFDA policies and regulations.
• The advisory board will play a crucial role in advising the authority on matters related to pharmaceuticals and medical devices.

The meeting was a crucial step in the implementation of the regulation, which aims to enhance the EFDA's regulatory framework and ensure compliance with international standards.

The Ethiopian Food and Drug Authority's (EFDA) Advisory Board held its inaugural meeting in Addis Ababa on August 15, 2025. The board was established under Council of Ministers Regulation No. 531/2023, which outlines its structure, powers, and duties. This marks a significant development for the EFDA, as the advisory board is tasked with providing guidance on policy, short-term, and long-term strategic decisions affecting the authority's operations.

The meeting was a crucial step in the implementation of the regulation, which aims to enhance the EFDA's regulatory framework and ensure compliance with international standards. The advisory board will play a pivotal role in advising the authority on matters related to pharmaceuticals, medical devices, and other healthcare products.

Council of Ministers Regulation No. 531/2023 is the legislative framework governing the EFDA's Advisory Board. The regulation defines the board's organization, powers, and responsibilities, ensuring that it operates within the bounds of the law. This regulatory framework is crucial for pharmaceutical companies operating in Ethiopia, as it sets out the rules and guidelines for the industry.

The establishment of the advisory board reflects the government's commitment to strengthening the EFDA's regulatory capacity and enhancing its ability to ensure public health and safety. The regulation also emphasizes the importance of international cooperation and collaboration in the field of pharmaceuticals and medical devices.

The meeting of the EFDA's Advisory Board has significant implications for pharmaceutical companies operating in Ethiopia. Any updates to the authority's policies and regulations may impact these companies' operations, making it essential for them to stay informed about developments in this area.

Lawyers specializing in healthcare compliance should closely monitor the situation, as changes to the EFDA's regulatory framework could have far-reaching consequences for pharmaceutical companies. The advisory board's recommendations will likely shape the future of pharmaceutical regulation in Ethiopia, highlighting the need for close attention from industry stakeholders and legal professionals.

Lawyers should watch for potential updates to EFDA's policies and regulations following the first meeting of its Advisory Board, which may impact pharmaceutical companies operating in Ethiopia.

Source: Original reporting via Ethiopian Food and Drug Authority news